ADDED
This Annual Report on Form 10-K also may include data based on our own internal estimates and research, including estimates regarding our consolidated financial statements and business operations.
On January 16, 2024, we effected a reverse split of our common stock, either issued and outstanding or held by us as treasury stock, (the January 2024 Reverse Split ) previously approved by our Board and stockholders.
On December 4, 2024, we effected a reverse split of our common stock, either issued and outstanding or held by us as treasury stock, (the December 2024 Reverse Split ) previously approved by our Board and stockholders.
On May 15, 2025, we effected a reverse split of our common stock, either issued and outstanding or held by us as treasury stock, (the May 2025 Reverse Split ) previously approved by our Board and stockholders.
The May 2025 Reverse Split was at a ratio of one share for every 28 shares previously held with no change in the par value per share.
The May 2025 Reverse Split did not change the number of authorized shares of common stock.
BUSINESS Overview TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers.
Our lead therapeutic product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA.
In addition to other RNA-targeted product candidates, we are conducting research and development of a cancer vaccine product candidate and an oncolytic immunotherapy platform.
On October 8, 2025, we entered into a Membership Interest Purchase Agreement (the Purchase Agreement ) with DEFJ, LLC, a Delaware limited liability company, ( DEFJ ) pursuant to which we acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company, ( ABCJ ) (such transaction, the Acquisition ).
REMOVED
This Annual Report on Form 10-K also may include data based on our own internal estimates and research, including estimates regarding the impact of the COVID-19 pandemic (or related pandemic caused by coronavirus variants) on our financial statements and business operations.
These risks are described more fully elsewhere in this Annual Report on Form 10-K and include, but are not limited to, the following: our low cash position and our estimates and expectations regarding our capital requirements, cash and expense levels, liquidity sources and our ability to obtain, on satisfactory terms or at all, the financing required to support operations, research, development, clinical trials, and commercialization of products; our business is highly dependent on the success of TTX-MC138, our lead therapeutic candidate which is at the early stages of development.
On January 16, 2024, the Company effected a reverse split of the Company s common stock, either issued and outstanding or held by the Company as treasury stock, (the January 2024 Reverse Split ) previously approved by the Board and stockholders of the Company.
On December 4, 2024, the Company effected a reverse split of the Company s common stock, either issued and outstanding or held by the Company as treasury stock, (the December 2024 Reverse Split ) previously approved by the Board and stockholders of the Company.
BUSINESS Overview TransCode is an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics.
TransCode has created a design engine to customize the development of RNA therapeutics.
Our engine is modular, both at the levels of the core delivery vehicle, which we call TTX, and with respect to therapeutic loading.
The size, charge, and surface chemistry of TTX can be tuned to optimize (i) delivery to the intended genetic target and (ii) the therapeutic load.
Food and Drug Administration, or FDA, an exploratory Investigational New Drug application, or eIND, on November 30, 2022.
The eIND was to conduct a First-in-Human, or FIH, clinical trial with a radiolabeled form of TTX-MC138 called TTX-MC138-NODAGA-Cu 64 .